湿包裹治疗13例儿童重度特应性皮炎临床效果观察

目的 观察湿包裹疗法(WWT)治疗儿童重度特应性皮炎(AD)的效果和安全性.方法 2016年9月至2017年3月在北京儿童医院皮肤科收集重度AD患儿(符合Williams诊断标准,SCORAD＞50分)13例,每日接受WWT,共治疗3～5d,评估治疗前后患儿SCORAD评分及VAS评分改善情况.选取其中3例患儿双侧肢体对称皮损进行WWT与传统治疗的对比观察,比较治疗3d后双侧局部皮损严重度评分.结果 13例患儿治疗前SCORAD评分及VAS评分分别为60.2±9.7和7.3±1.8,WWT治疗3～5d后,分别降至24.7±5.8和2.4±1.0,治疗前后差异均有统计学意义(t值分别为15.128、9.385,均P＜ 0.001);12例患儿SCORAD改善率达50％以上.3例患儿双侧皮损治疗3d后,WWT侧皮损严重度评分低于对照侧(t=7.0,P＜ 0.05).WWT不良反应轻微,3例患儿主诉治疗过程中潮湿引起不适感.结论 WWT治疗儿童重度AD起效快,不良反应少,效果优于传统单纯外用药物.     

湿包裹治疗在儿童重度特应性皮炎中的应用

儿童重度特应性皮炎(atopic dermatitis,AD)因系统用药受年龄及不良反应的限制常缺乏有效治疗方法,而湿包裹治疗(wet-wrap treatment,WWT)是对反复难治性重度AD的一种有效且相对安全的方法。WWT是指在外用药物及润肤的基础上,使用双层管状绷带或纱布包裹治疗的一种治疗模式。在国际上广泛用于治疗各种瘙痒性皮肤疾病,尤其是儿童重度AD,与传统外用药物治疗比较的优势在于起效迅速、修复皮肤屏障,并显著控制瘙痒,从而改善生活质量,同时减少系统药物的应用。WWT目前报告不良反应较少,通常较轻微,且为一过性。该方法在国内尚无相关报道。     

血清维生素D水平与婴儿特应性皮炎严重度的相关性研究

目的 检测婴儿特应性皮炎(AD)患者血清维生素D水平,了解血清维生素D与婴儿AD严重程度之间的关系.方法 2016年2-4月在山西省儿童医院采用问卷调查方式采集中重度AD组基本信息,参考SCORAD评分法评估疾病严重程度.酶联免疫吸附试验检测AD组和对照组(95例健康体检者)血清25-羟基维生素D3水平以及AD组血清总IgE水平,血细胞分析仪检测AD组血嗜酸性粒细胞比例.结果 97例AD患儿完成研究,中度43例(44.3％),重度54例(55.7％).AD组血清25-羟基维生素D3水平[(66.71±21.07) nmol/L]低于健康对照组[(85.43±14.87) nmol/L,P＜0.01)],重度组[(47.54±29.36) nmol/L]低于中度组[(63.89±26.67)nmol/L,P=0.006].重度AD组嗜酸性粒细胞比例(0.124±0.094)高于中度组(0.061±0.060)(P＜ 0.001).中度AD组与重度AD组血清总IgE水平差异无统计学意义(P=0.375).AD患者血清25-羟基维生素D3水平与嗜酸性粒细胞比例呈负相关(r=-0.336,P＜0.05),但与血清总IgE水平之间无相关性(r=-0.174,P＞0.05).母乳喂养、补充维生素D与25-羟基维生素D3水平显著相关(P＜0.05),而年龄、性别、AD病程、急性期渗出与25-羟基维生素D3水平无显著相关性(均P＞0.05).结论 婴儿期AD患者血清25-羟基维生素D3水平明显下降,维生素D缺乏与婴儿期AD的严重程度密切相关.     

经尿道前列腺电切术对不同类型良性前列腺增生患者的治疗效果研究

目的 探讨不同类型良性前列腺增生(BPH)患者采取经尿道前列腺电切术(TURP)的治疗效果.方法 选取2014年9月至2017年9月新疆医科大学附属中医医院收治的158例BPH患者作为研究对象,将患者分为腺型结节组(n=40)、纤维腺瘤型结节组(n=42)、腺肌型结节组(n=39)、血管增生型结节组(n=37).四组均...     

中、重度特应性皮炎的诊断和治疗进展

特应性皮炎（AD）是一种慢性、瘙痒性、炎症性皮肤病。全世界的患病率成人达2% ~ 5%,儿童达10% ~ 20％［1］,其中20%属于中、重度［2］。AD发病机制复杂,涉及免疫系统过度活化、上皮屏障功能障碍和皮肤微生物群失调等诸多方面［3?5］。轻度患者可外用润肤剂、糖皮质激素（简称激素）或钙调磷酸酶抑制剂治疗［6］,中、重度患者常需联合免疫抑制剂甚至生物制剂治疗［7］。AD诊断标准众多,如Hanifin和Rajka标准、Williams标准等［8］,但对于中、重度AD的诊断目前尚无统一标准。现从近年来国内外常用的AD诊疗指南入手,结合近年中、重度AD患者进行的临床试验,对中、重度AD的诊断标准进行评价并对其治疗进展进行概述……     

系统性红斑狼疮患者血清β2-MG水平与肾损害程度的相关性

目的 探讨系统性红斑狼疮(SLE)患者血清β2微球蛋白(β2-MG)水平与肾损害程度的相关性.方法 回顾性收集2015年7月至2020年7月河南省荥阳市人民医院检验科接受治疗的81例SLE患者临床资料,根据肾损害程度分为轻度组(n=29)、中度组(n=28)与重度组(n=24).所有患者均接受β2-MG水平检查,并分析...     

疏肝益阳胶囊联合文拉法辛治疗早泄伴有勃起功能障碍的临床观察

目的:探讨疏肝益阳胶囊联合文拉法辛治疗早泄伴有勃起功能障碍患者的临床疗效。方法:本文选择我院2015年4月至2016年4月收治的157例患者随机分为治疗组(n=79)和对照组(n=78)。对照组采用文拉法辛治疗,治疗组在对照组的基础上联合疏肝益阳胶囊治疗。观察比较两组IIEF-5评分、CIPE-5评分、HAD评分及不良反应发生情况。结果:治疗后IIEF-5评分比较,治疗组有效率为97.47%高于对照组70.51%(Z=-4.024,P=0.000)。治疗组CIPE-5评分轻度比率为63.29%,中度比率为29.11%高于对照组CIPE-5评分轻度比率为55.13%,中度比率为24.36%,而重度比率为7.59%低于对照组的重度比率20.51%(Z=-5.877,P=0.000)。治疗后,两组焦虑和抑郁评分与治疗前比较均显著降低(P0.01),且治疗组与对照组比较亦显著降低(P0.01)。治疗组不良反应率为6.33%显著低于对照组19.23%(χ~2=6.499,P=0.043)。结论:疏肝益阳胶囊联合文拉法辛治疗PE伴ED临床疗效显著,CIPE-5评分重度比率明显下降,焦虑和抑郁评分下降,不良反应轻,可以有效改善患者生活质量,值得推广应用。     

308nm准分子激光与NB-UVB治疗白癜风的效果对比分析

目的对比分析308nm准分子激光(MEL)与311nm窄谱中波紫外线(NB-UVB)治疗白癜风的治疗效果。方法选择2015年9月～2017年9月我院收治的白癜风患者104例为研究对象,依照治疗方法分为MEL组(n=52,给予308nm的MEL治疗)和UVB组(n=52,给予311nm的NB-UVB治疗),比较其治疗效果和不良反应。结果 MEL组75.00%的治疗总有效率显著高于UVB组的55.76%(P 0.05);MEL组7.69%的不良反应总发生率显著低于UVB组的23.08%(P 0.05)。结论 308nm的MEL对白癜风患者治疗效果更好,安全性更高。     

妊娠期高血压疾病患者外周血miR-15-5P和妊娠相关血浆蛋白A 水平动态监测的价值分析

目的 探讨动态监测外周血微小RNA-15-5P(miR-15-5P)和妊娠相关血浆蛋白A (PAPP-A)水平在妊娠期高血压疾病(HDCP)患者治疗中的临床价值。方法 回顾性分析2019年7月至2021年6月于唐山市妇幼保健院就诊的165例HDCP患者的临床资料,纳入病例组,并根据病情严重程度分为妊娠高血压组(n=67)、轻度子痫前期组(n=63)、重度子痫前期组(n=35);选择同期在同一医院产检的91例正常妊娠女性作为对照组。所有研究对象均留取孕10、20、36周及产后1周的空腹静脉血,采用荧光定量聚合酶链反应(PCR)法测定miR-15-5P的表达水平,酶联免疫吸附试验(ELISA)法测定PAPP-A的血清含量。结果 病例组和对照组的miR-15-5P水平均随着孕周的增加而降低,PAPP-A水平随着孕周的增加而升高,两组任意时间点的差异均具有统计学意义(P<0.05)。病例组在孕10、20、36周及产后1周的miR-15-5P水平均低于对照组,且妊娠高血压组、轻度子痫前期组、重度子痫前期组同一时间点依次降低,差异均具有统计学意义(P<0.05)。病例组在孕10、20、...     

特应性皮炎和湿疹患者血清金黄色葡萄球菌肠毒素B特异性抗体的检测及其意义

目的 探讨特应性皮炎(AD)和湿疹患者血清金黄色葡萄球菌肠毒素B(SEB)特异性抗体水平及其意义。方法 采用多中心、随机双盲、对照法,将118例AD和207例湿疹患者分为莫匹罗星治疗组和对照组,于治疗前和治疗28d取血清行间接酶联免疫吸附测定法测定抗SEB特异性IgG、IgM水平,采用链霉亲和素-生物素法检测抗SEBIgE水平。结果 治疗前,抗SEBIgE水平AD组显著高于正常人对照组(P=0.019)和湿疹组(P=0.048),湿疹组与正常人对照组之间差异无统计学意义(P=0.883);抗SEBIgM水平AD组(P=0.012)和湿疹组(P=0.000)均显著高于正常人对照组,AD组与湿疹组之间差异无统计学意义(P=0.088);抗SEBIgG水平各组间均差异无统计学意义(P=0.897)。临床症状评分与抗SEBIgE水平之间AD组(P=0.842)和湿疹组(P=0.134)均无显著相关性。治疗28d后,抗SEBIgM水平AD组显著下降(P=0.003),湿疹组亦显著下降(P=0.000),但治疗组与对照组间AD组(P=0.331)和湿疹组(P=0.815)差异均无统计学意义。结论 AD和湿疹患者血中抗SEBIgM、IgE升高,反映皮损处近期金黄色葡萄球菌定植并参与了皮肤变应性炎症性反应。     

联合臭氧水治疗特应性皮炎患者的疗效及白细胞介素4、神经生长因子检测

目的：观察联合臭氧水治疗特应性皮炎（AD）患者的临床疗效和安全性。方法收集6~65岁中重度AD患者，分为试验组和对照组，每组30例。两组患者均口服左西替利嗪胶囊（5 mg每日1次），外涂他克莫司软膏，每日2次，同时外涂保湿润肤霜。试验组加用臭氧水疗，每周3~5次。共观察2周。观察两组患者治疗前后特应性皮炎严重度评分（SCORAD）评分、视觉模拟尺（VAS）瘙痒评分、皮肤病生活质量指数（DLQI）/儿童皮肤病生活质量指数（CDLQI）变化情况，ELISA法检测患者治疗前后外周血白细胞介素4、神经生长因子表达水平。结果试验组患者治疗前SCORAD评分、VAS评分、DLQI/CDLQI评分分别为42.13±16.03、7.14±2.12、14.92±5.94，治疗2周后分别为27.3±11.01、2.23±1.31、9.69±4.17；对照组治疗前SCORAD评分、VAS评分、DLQI/CDLQI评分分别为43.36±17.78、6.45±1.29、15.15±5.40，治疗2周后分别为39.65±16.67、3.32±0.87、12.84±5.37。两组3种评分治疗前后比较，差异均有统计学意义（均P<0.05），且治疗2周后两组之间3种评分差异亦有统计学意义（均P<0.05）。两组患者治疗后外周血白细胞介素4和神经生长因子水平均下降，与治疗前相比，差异有统计学意义（均P<0.05），其中试验组白细胞介素4下降幅度大于对照组（t=8.57，P<0.05），神经生长因子下降幅度两组间差异无统计学意义（t=9.51，P>0.05）。结论联合臭氧水能安全、有效地改善AD患者病情，可能与降低患者外周血白细胞介素4水平有关。     

依巴斯汀三倍剂量治疗轻中度特应性皮炎的疗效和安全性

目的：评价依巴斯汀三倍剂量治疗特应性皮炎的有效性和安全性。方法：选取轻度至中度的特应性皮炎患者为研究对象,随机分为观察组和对照组。观察组口服依巴斯汀片30 mg/d联合医用凡士林外用,对照组口服依巴斯汀片10 mg/d联合医用凡士林外用,观察两组患者在28天治疗后的瘙痒评分、SCORAD总分、临床总有效率以及发生的不良反应。结果：共收集患者128例,其中观察组和对照组各64例,观察组的瘙痒评分、SCORAD总分分别为3.02±1.19和21.83±3.05均显著低于对照组的6.77±1.33和29.28±4.91（P<0.05）;观察组临床总有效率为93.33%高于对照组的68.75%,差异有统计学意义（P<0.05）;观察组不良反应发生率为6.3%,对照组为9.4%,两组不良反应比较无统计学差异（P＞0.05）。结论：与常规剂量的依巴斯汀比较,30 mg/d的依巴斯汀治疗特应性皮炎疗效优于10 mg/d,不良反应无明显差异。     

Wet-wrap treatment in children with atopic dermatitis: a practical guideline

Treatment of children with severe atopic dermatitis (AD) can be especially challenging because several possible intervention treatments have (relative) contraindications in childhood. In recent years, wet-wrap treatment (WWT) has been advocated as a relatively safe and efficacious intervention in children with severe or refractory AD. The goal of this article is to provide a practical guideline as a starting point for clinicians who are interested in using WWT in their own clinical practice. We will address several practical issues surrounding the use of WWT by describing our own experiences, supplemented with data from the literature.     

SCORAD 75: a new metric for assessing treatment outcomes in atopic dermatitis

Objective The scoring atopic dermatitis (SCORAD) is a well‐established severity‐scoring tool for atopic dermatitis (AD). Dead Sea climatotherapy (DSC) is a natural selective balneo‐phototherapy utilized for many years to treat severe AD. The study’s goal was to evaluate the impact of DSC on AD patients through assessment of SCORAD scores and to identify parameters associated with greater improvement. Methods The files of 78 European patients (37 male patients and 41 female patients, mean age 37.8 years) with AD undergoing DSC were included in this retrospective study. Three sub‐groups were delineated based on disease severity (as determined using the SCORAD). Demographic and clinical parameters as well as treatment characteristics – maximal and cumulative sun exposure doses – were recorded. SCORAD values were again recorded for assessment of treatment response. SCORAD 75 was defined as ≥75% decrease in SCORAD values following therapy. Statistical analysis including logistic regression models was used in multivariable analysis. Results After an average of 30 days of treatment, mean SCORAD values dropped from 50.5 to 11 (76.7%, P < 0.001). 64.1% of all patients, regardless of sub‐group, reached SCORAD 75, whereas 78.9% of patients with severe disease achieved this result. In a multivariate logistic regression, factors associated with achieving SCORAD 75 were maximal sun exposure, family history of AD and age at disease onset (P = 0.002, P = 0.009 and P = 0.040 respectively). Conclusion Dead Sea climatotherapy is a particularly effective treatment method for the sub‐population of adults with severe AD. The SCORAD 75 can be useful for defining sub‐populations in which treatment is more likely to be successful.     

The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study

BACKGROUND: No study has clearly demonstrated the steroid-sparing effect of emollients in the treatment of atopic dermatitis (AD). AIM: Evaluating the effect of an emollient containing oat extracts on the amount of topical corticosteroids used in infants with moderate to severe AD. STUDY DESIGN: During 6 weeks, 173 infants under 12 months old treated for inflammatory lesions by moderate- and/or high-potency topical corticosteroids randomly received the emollient or not (control group). METHODS: Evaluation of corticosteroid consumption by weighing the tubes, disease severity by the Scoring Atopic Dermatitis Index (SCORAD), and infants' and parents' quality of life by Infant's Dermatitis Quality of Life Index and Dermatitis Family Impact scores at D0, D21 and D42. RESULTS: Compared to the control group, the amount of moderate- and high-potency corticosteroids used in 6 weeks decreased by 7.5% (not significant) and 42% (p < 0.05), respectively, in the emollient group. The SCORAD index, and infants' and parents' quality of life significantly improved (p < 0.0001) in both groups. CONCLUSION: The emollient treatment significantly reduced the high-potency topical corticosteroid consumption in infants with AD.     

A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults

Leukotriene receptor antagonists are recommended for the treatment of asthma, and have proved anecdotally successful even in atopic dermatitis. Standard treatments of atopic dermatitis are often unsatisfactory. Accordingly, we compared montelukast, 10 mg/day, with a combined regimen (orally administered cetirizine and clarythromycin, topical corticosteroids and hydrating preparations) for treatment of moderate-to-severe atopic dermatitis of adults. The trial was designed as a randomized single-blind study. SCORAD, eosinophilic cationic protein (ECP), eosinophilic protein X (EPX) serum levels were assessed at baseline and after 6 weeks in 32 adult patients with atopic dermatitis (16 treated with montelukast; 16 treated with the combined regimen). Similar improvements, evaluated in term of SCORAD reductions, were detected in both groups (Mann-Whitney, p < 0.05), while ECP and EPX levels significantly reduced within each group (Welch's approximate t, p < 0.05). We conclude that montelukast is as effective as the comparison combined regimen to treat atopic dermatitis of adults.     

健脾止痒颗粒治疗特应性皮炎临床观察

目的探讨中药健脾止痒颗粒治疗特应性皮炎(AD)的有效性和安全性。方法将入选AD患者随机分为治疗组(健脾止痒颗粒)32例和对照组(氯雷他定)32例,连续服药4周。采用欧洲AD评分标准(SCORAD)对AD的临床严重度进行评分,用视觉模拟尺度(VAS)评分法对瘙痒程度进行评分;同时记录SCORAD积分和VAS积分。疗程结束后,评价疗效。结果治疗组及对照组治疗4周后,SCORAD积分下降(P<0.05)、VAS积分明显下降(P<0.01)。有效率前者为84.4%,后者为43.8%。两组疗效经统计学处理,差异有显著性(χ2=12,P<0.01)。两组病例未见明显不良反应。结论健脾止痒颗粒治疗AD疗效确切,能明显降低患者SCORAD积分和VAS积分。其有效机制有待深入研究。     

Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity

BACKGROUND: It is currently fashionable to consider atopic dermatitis (AD), like other inflammatory dermatoses, as immunologic in pathogenesis ("inside-outside" hypothesis). Accordingly, topical glucocorticoids and other immunosuppressive agents are mainstays of therapy, but the risk of toxicity from these agents is not insignificant, particularly in children. Alternatively, because stratum corneum (SC) permeability barrier function is also abnormal in AD, it has been hypothesized that the barrier abnormality could drive disease activity. Yet commonly used emollients and moisturizers do not correct the SC ceramide deficiency, the putative cause of the barrier abnormality. OBJECTIVES: We assessed the efficacy of a newly developed, ceramide-dominant, physiologic lipid-based emollient, when substituted for currently used moisturizers, in 24 children who were also receiving standard therapy for stubborn-to-recalcitrant AD. METHODS: All subjects continued prior therapy (eg, topical tacrolimus or corticosteroids), only substituting the barrier repair emollient for their prior moisturizer. Follow-up evaluations, which included severity scoring of atopic dermatitis (SCORAD) values and several biophysical measures of SC function, were performed every 3 weeks for 20 to 21 weeks. RESULTS: SCORAD values improved significantly in 22 of 24 patients by 3 weeks, with further progressive improvement in all patients between 6 and 20 or 21 weeks. Transepidermal water loss levels (TEWL), which were elevated over involved and uninvolved areas at entry, decreased in parallel with SCORAD scores and continued to decline even after SCORAD scores plateaued. Both SC integrity (cohesion) and hydration also improved slowly but significantly during therapy. Finally, the ultrastructure of the SC, treated with ceramide-dominant emollient, revealed extracellular lamellar membranes, which were largely absent in baseline SC samples. CONCLUSION: These studies suggest that (1) a ceramide-dominant, barrier repair emollient represents a safe, useful adjunct to the treatment of childhood AD and (2) TEWL is at least as sensitive an indicator of fluctuations in AD disease activity as are SCORAD values. These studies support the outside-inside hypothesis as a component of pathogenesis in AD and other inflammatory dermatoses that are accompanied by a barrier abnormality.     

Wet-wrap treatment using dilutions of tacrolimus ointment and fluticasone propionate cream in human APOC1 (+/+) mice with atopic dermatitis

Background  Wet-wrap treatment (WWT) with diluted topical steroids is widely used in atopic dermatitis (AD). Mice with transgenic overexpression of human apolipoprotein C1 (APOC1) in the liver and the skin are not only characterized by hyperlipidaemia and raised IgE levels, but also by pruritic dermatitis and a disturbed skin barrier function, providing a novel in vivo mouse model for AD.
Objectives  We investigated an adapted WWT method in the AD model in APOC1 mice in order to establish its efficacy.
Methods  The effect of topical 0·1% and 0·03% tacrolimus ointment, tacrolimus base ointment, different dilutions of 0·05% fluticasone propionate (FP) cream and emollient on the development of dermatitis in APOC1 mice was investigated. WWT was performed with 0·03% tacrolimus ointment or 0·017% FP cream.
Results  AD in APOC1 mice responded to topical treatment with tacrolimus or FP. In contrast to tacrolimus treatment, FP treatment was associated with loss of body weight. WWT reinforced several therapeutic aspects, notably improvements in transepidermal water loss and in epidermal thickness. WWT using tacrolimus 0·03% ointment was more effective than WWT using FP 0·017% cream.
Conclusions  AD in APOC1 mice responds to treatment with (diluted) tacrolimus or FP; treatment with FP cream, but not tacrolimus ointment, was associated with weight loss. In this study, the adapted WWT using tacrolimus or FP in mice had a limited improving effect as compared with open application of tacrolimus or FP.